Psyence Biomedical Ltd. (NASDAQ:PBM – Get Free Report) was the target of a significant decline in short interest during the month of November. As of November 15th, there was short interest totalling 11,000 shares, a decline of 98.4% from the October 31st total of 671,900 shares. Currently, 1.8% of the company’s shares are short sold. Based on an average trading volume of 104,900 shares, the short-interest ratio is presently 0.1 days.
Hedge Funds Weigh In On Psyence Biomedical
An institutional investor recently bought a new position in Psyence Biomedical stock. Virtu Financial LLC bought a new position in shares of Psyence Biomedical Ltd. (NASDAQ:PBM – Free Report) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 26,419 shares of the company’s stock, valued at approximately $30,000. Virtu Financial LLC owned about 0.30% of Psyence Biomedical at the end of the most recent quarter. 77.44% of the stock is owned by institutional investors and hedge funds.
Psyence Biomedical Stock Up 5.1 %
NASDAQ PBM traded up $0.17 during trading on Wednesday, hitting $3.51. The stock had a trading volume of 142,109 shares, compared to its average volume of 57,366. The stock has a 50 day simple moving average of $0.15 and a 200 day simple moving average of $0.38. Psyence Biomedical has a one year low of $3.01 and a one year high of $323.25.
About Psyence Biomedical
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company’s lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care.
See Also
- Five stocks we like better than Psyence Biomedical
- What is Put Option Volume?
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
- Airline Stocks – Top Airline Stocks to Buy Now
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- ESG Stocks, What Investors Should Know
- 2 Generic Drug Stocks Ready to Surge in 2025
Receive News & Ratings for Psyence Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Psyence Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.
